A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx
A new vascular ultrasound contrast agent under development by ImaRx Pharmaceutical has finishedphase I clinical trials, the Tucson company said this month. MRX-115Aerosomes is the first ImaRx agent based on the company's Aerosomestechnology, which ImaRx claims may be able to significantly enhancegray-scale ultrasound scans in cardiac, blood pool, kidney andliver imaging.
MRX-115 Aerosomes consists of sterile phospholipid-coated microbubbleswith a mean diameter of 2.5 microns. ImaRx plans to use the Aerosomestechnology to develop targeted, site-specific agents for imagingand drug delivery for lymph nodes and diseased tissue.
ImaRx said the phase I trials gave positive results for useof MRX-115 in myocardial perfusion imaging and indicated thatthe agent has a wide safety profile relative to the dose neededfor clinical efficacy. Phase II trials will begin later this year,and ImaRx plans to pursue additional indications for MRX-115 suchas imaging of liver and kidney perfusion.
ImaRx is the developer of SonoRx, an oral ultrasound contrastagent for abdominal imaging under license to Bracco Diagnostics(SCAN 7/27/94 and 3/10/93).
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.